Cargando…

Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study

As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgent need for new and effective therapeutic alternatives for selected cases with severe disease. Bortezomib (BTZ) is a specific, reversible, inhibitor of the 20S subunit of the proteasome. Herein, we rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walhelm, Tomas, Gunnarsson, Iva, Heijke, Rebecca, Leonard, Dag, Trysberg, Estelle, Eriksson, Per, Sjöwall, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517506/ https://www.ncbi.nlm.nih.gov/pubmed/34659263 http://dx.doi.org/10.3389/fimmu.2021.756941

Ejemplares similares

Fighting Fatigue in Systemic Lupus Erythematosus: Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes
por: Skoglund, Oliver, et al.
Publicado: (2022)

Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity
por: Svenungsson, Elisabet, et al.
Publicado: (2021)

Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
por: Eriksson, Per, et al.
Publicado: (2019)

Longitudinal Analysis of Anti-cardiolipin and Anti-β2-glycoprotein-I Antibodies in Recent-Onset Systemic Lupus Erythematosus: A Prospective Study in Swedish Patients
por: Frodlund, Martina, et al.
Publicado: (2021)

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms
por: George-Chandy, Annie, et al.
Publicado: (2008)

Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes
por: Ahmad, A., et al.
Publicado: (2020)

Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus
por: Torell, Agnes, et al.
Publicado: (2023)

Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus
por: Heijke, Rebecca, et al.
Publicado: (2020)

Comparing longitudinal patient-reported outcome measures between Swedish patients with recent-onset systemic lupus erythematosus and early rheumatoid arthritis
por: Heijke, Rebecca, et al.
Publicado: (2021)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Sex differences in clinical presentation of systemic lupus erythematosus
por: Ramírez Sepúlveda, Jorge I., et al.
Publicado: (2019)

Contributions of de novo variants to systemic lupus erythematosus
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2020)

Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement
por: Trysberg, Estelle, et al.
Publicado: (2004)

Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study
por: Heijke, Rebecca, et al.
Publicado: (2021)

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
por: Alexander, Tobias, et al.
Publicado: (2015)

Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus
por: Svensson, Christina, et al.
Publicado: (2021)

Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus
por: Trysberg, Estelle, et al.
Publicado: (2004)

Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2019)

DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus
por: Imgenberg-Kreuz, Juliana, et al.
Publicado: (2018)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Novel risk genes for systemic lupus erythematosus predicted by random forest classification
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2017)

Therapeutic inhibition of proteasomes in systemic lupus erythematosus
por: Hiepe, Falk, et al.
Publicado: (2011)

High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus
por: Svensson, Christina, et al.
Publicado: (2020)

The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus
por: Bremme, Katarina, et al.
Publicado: (2021)

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
por: Leonard, Dag, et al.
Publicado: (2018)

Shared and Unique Patterns of DNA Methylation in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome
por: Imgenberg-Kreuz, Juliana, et al.
Publicado: (2019)

Comment on: Sudanese and Swedish patients with systemic lupus erythematosus, immunological and clinical comparisons: reply
por: Elbagir, Sahwa, et al.
Publicado: (2020)

Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus
por: Wirestam, Lina, et al.
Publicado: (2015)

Four Systemic Lupus Erythematosus Subgroups, Defined by Autoantibodies Status, Differ Regarding HLA‐DRB1 Genotype Associations and Immunological and Clinical Manifestations
por: Diaz‐Gallo, Lina‐Marcela, et al.
Publicado: (2021)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2020)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus
por: Reid, Sarah, et al.
Publicado: (2021)

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
por: Sjöwall, Christopher, et al.
Publicado: (2009)

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus
por: Idborg, Helena, et al.
Publicado: (2018)

Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study
por: Karlsson, Linnea, et al.
Publicado: (2023)

Successful Treatment with Bortezomib for Refractory Thrombotic Thrombocytopenic Purpura Associated with Systemic Lupus Erythematosus
por: Yan, Ruyu, et al.
Publicado: (2022)

NET Formation in Systemic Lupus Erythematosus: Changes during the COVID-19 Pandemic
por: Knopf, Jasmin, et al.
Publicado: (2022)

C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205
por: Enocsson, Helena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_868gcj809go9uh734id33qd3ga